Supplementary Figure S1 from Comparison of Circulating Tumor DNA Assays for Molecular Residual Disease Detection in Early-Stage Triple-Negative Breast Cancer

Maria Coakley; Guillermo Villacampa; Prithika Sritharan; Claire Swift; Kathryn Dunne; Lucy Kilburn; Katie Goddard; Christodoulos Pipinikas; Patricia Rojas; Warren Emmett; Peter Hall; Catherine Harper‐Wynne; Tamas Hickish; Iain R. Macpherson; Alicia Okines; Andrew Wardley; Duncan Wheatley; Simon Waters; Carlo Palmieri; Matthew Winter; Rosalind J. Cutts; Isaac García-Murillas; Judith M. Bliss; Nicholas C. Turner

doi:10.1158/1078-0432.25232567.v1

Abstract

Correlation between the tumor fraction percentage as reported by mean Variant Allele Frequency (mean VAF) or estimated Variant Allele Frequency (eVAF) for the RaDaR ctDNA assay.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Coakley et al. (2024) studied this question.

synapsesocial.com/papers/68e78e41b6db64358770035d https://doi.org/10.1158/1078-0432.25232567.v1

View Full Paper

Ask AI

Bookmark

Share

Supplementary Figure S1 from Comparison of Circulating Tumor DNA Assays for Molecular Residual Disease Detection in Early-Stage Triple-Negative Breast Cancer

Abstract

Discussion

Cite This Study

Supplementary Figure S1 from Comparison of Circulating Tumor DNA Assays for Molecular Residual Disease Detection in Early-Stage Triple-Negative Breast Cancer

Abstract

Discussion

Cite This Study

Keep reading

More related papers

Keep reading

More related papers